FeesSafety
Pluang+

Titan International reports Q3 revenue of $335M, plans to sell ITM business to focus on core wheel and tire operations.

Company Fundamentals
29 Oct 2026, 13:00 WIB
PRNewsWire
View Source
Neutral
Titan International reports Q3 revenue of $335M, plans to sell ITM business to focus on core wheel and tire operations.

Titan International reported Q3 2026 revenues of $335 million from continuing operations and $454 million including discontinued ITM operations. The company plans to sell its ITM undercarriage business by January 2027 to focus on its core wheel and tire segments and reduce debt. Despite market challenges like high interest rates and input costs, Titan saw growth in its EMC segment and expects improved demand due to aging machinery and low inventory levels. The company updated its Q4 and full-year 2026 guidance, anticipating sales between $1.85 and $1.87 billion and adjusted EBITDA between $91 million and $101 million.

Titan International's Q3 2026 revenue from continuing operations reached $335 million, with total revenue including discontinued ITM operations at $454 million. For readers following the Industrials sector, here is Pluang's market snapshot as of Oct 29, 2026 15:11 WIB: out of 135 priced US Industrials stocks, 72 rose and 57 fell. Notable movers include Bloom Energy (BE) at USD 216.55 with a 1-day change of -5.06% and 82% sell order activity, INNIO N.V. (INIO) at USD 17.51 down 4.58% with 100% sell orders, and Vertiv Holdings Co (VRT) at USD 233.54 down 3.87% with balanced buy/sell orders.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
15 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
15 minutes ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
1 hour ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
1 hour ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App